Roniciclib is an orally bioavailable, small molecule pan-cyclin-dependent kinase (CDK) inhibitor investigated for the treatment of small cell lung carcinoma. By selectively targeting various CDK isoforms,… Read more
Roniciclib is an orally bioavailable, small molecule pan-cyclin-dependent kinase (CDK) inhibitor investigated for the treatment of small cell lung carcinoma. By selectively targeting various CDK isoforms, including CDK1, 2, 4, 7, and 9, this compound interferes with pathways that regulate the cell cycle and tumor cell proliferation. To support the rigorous demands of pharmaceutical research and development, this category provides a range of high-quality reference standards for Roniciclib, including the active pharmaceutical ingredient (API) and its associated derivatives. Laboratories rely on these materials, such as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds, to perform precise impurity profiling and analytical method validation. These essential tools facilitate comprehensive quality control, ensuring that every stage of drug development meets the necessary safety and efficacy standards while enabling accurate detection and quantification of potential process-related substances.